natgillin/translations-raw huggingface dataset:
Very common side effects • bone, joint and muscle pain • elevations in blood levels of uric acid and certain enzymes • decreases in blood glucose • leukocytosis (an abnormally high number of white blood cells in the blood) • low level of blood platelets (which increases risk of bleeding or bruising) • low level of red blood cells (which can make the skin pale and cause weakness and breathlessness) • headache • nose bleed • enlarged spleen
Zelo pogosti neželeni učinki • bolečine v kosteh, sklepih in mišicah • povečanje ravni sečne kisline in določenih encimov v krvi • zmanjšana koncentracija glukoze v krvi • levkocitoza (nenormalno visoko število belih krvnih celic v krvi) • nizka raven trombocitov (kar poveča tveganje za krvavitev ali modrice) • nizka raven rdečih krvnih celic (kar lahko povzroči bledico kože, slabotnost in zadihanost) • glavobol • krvavenje iz nosu • povečana vranica
Common side effects • diarrhoea • injection site pain • hair loss • rash • enlarged liver • inflammation of blood vessels of the skin • loss of calcium from the bones (osteoporosis) • spleen disorder
Pogosti neželeni učinki • driska • bolečina na mestu injiciranja • izpadanje las • kožni izpuščaj
55 Uncommon side effects • decrease in blood pressure • allergic-type reactions, including anaphylaxis (dizziness, severe drop in blood pressure, difficulty in breathing), angioedema (painful swelling of the face or throat), difficulty in breathing, low blood pressure, skin rash, nettle rash; these reactions can occur at the start of the treatment or throughout the treatment • worsening of rheumatoid arthritis or arthritic symptoms • blood or protein in the urine
55 • povečana jetra • vnetje krvnih žil v koži • izgubljanje kalcija iz kosti (osteoporoza), • bolezni vranice
Rare side effects • vascular disorders, including venoocclusive disease (a disease which affects the liver) and water retention, which can cause swelling in the limbs
Redki neželeni učinki • žilne bolezni, vključno z vensko zaporo (obolenje, ki prizadene jetra) in zadrževanjem vode, kar lahko povzroči otekanje okončin
Very rare side effects • difficulties in passing urine • Sweet's syndrome (plum-coloured, raised, painful lesions on the limbs, sometimes the face and neck, with fever) • water retention in the lungs, bleeding in the lungs, coughing up of blood, lack of oxygen, inflammation of the lungs (which can cause breathlessness, cough, raised temperature); in some cases, this could lead to respiratory failure or adult respiratory distress syndrome (ARDS, a condition causing increased shortness of breath, in very ill patients), which may be fatal • sickle cell crises (acute collapse of red blood cells) in patients with sickle cell disease • rupture of the spleen
Zelo redki neželeni učinki • težave pri odvajanju urina • Sweetov sindrom (izbočene boleče poškodbe slivove barve na okončinah, včasih na obrazu in vratu, z zvišano telesno temperaturo) • zastajanje vode v pljučih, krvavenje v pljučih, izkašljevanje krvi, pomankanje kisika, pljučno vnetje (ki lahko povzroči zadihanost, kašelj, zvišano telesno temperaturo); v nekaterih primerih to lahko vodi v dihalno odpoved ali sindrom dihalne stiske pri odraslem (ARDS, stanje, ki povzroča povečano kratko sapo pri hudo bolnih osebah), kar lahko vodi v smrt. • srpastocelične krize (akuten kolaps rdečih krvničk) pri bolnikih s srpastoceličnim obolenjem • raztrganje vranice
HOW TO STORE FILGRASTIM HEXAL
SHRANJEVANJE ZDRAVILA FILGRASTIM HEXAL
Do not use Filgrastim HEXAL after the expiry date which is stated on the carton and on the syringe label after EXP.
Zdravila Filgrastim HEXAL ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na nalepki brizge poleg oznake "Uporabno do/ EXP".
Store in a refrigerator (2°C - 8°C).
Zdravilo Filgrastim HEXAL shranjujte v hladilniku (pri temperaturi od 2°C do 8°C).
Keep the pre-filled syringe in the outer carton in order to protect from light.
Napolnjeno injekcijsko brizgo shranjujte v zunanjem pakiranju, za zagotovitev zaščite pred svetlobo.
What Filgrastim HEXAL contains
Kaj vsebuje zdravilo Filgrastim HEXAL
Filgrastim HEXAL 30 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe:
56 Filgrastim HEXAL 30 M e. / 0, 5 ml raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi:
Each pre-filled syringe contains 30 MU filgrastim in 0.5 ml, corresponding to 60 MU/ ml.
Ena napolnjena injekcijska brizga vsebuje 30 milijonov enot filgrastima v 0, 5 ml, kar ustreza 60 M e. / ml.
Filgrastim HEXAL 48 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe:
Filgrastim HEXAL 48 M e. / 0, 5 ml raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi:
Each pre-filled syringe contains 48 MU filgrastim in 0.5 ml, corresponding to 96 MU/ ml
Ena napolnjena injekcijska brizga vsebuje 48 milijonov enot filgrastima v 0, 5 ml, kar ustreza 96 M e. / ml.
- The other ingredients are glutamic acid, sorbitol (E420), polysorbate 80 and water for
- Pomožne snovi so: glutaminska kislina, sorbitol (E 420), polisorbat 80 in voda za injekcije.
56 What Filgrastim HEXAL looks like and contents of the pack
Izgled zdravila Filgrastim HEXAL in vsebina pakiranja
Filgrastim HEXAL is a clear, colourless to slightly yellowish solution for injection or infusion in a pre-filled syringe.
Zdravilo Filgrastim HEXAL je bistra, brezbarvna do rahlo rumenkasta raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi.
Not all pack sizes may be marketed.
Na trgu ni na voljo vseh navedenih pakiranj.
HEXAL AG Industriestrasse 25 D-83607 Holzkirchen Germany Tel: + 49 8024 908-0 Fax: + 49 8024 908-1290 e-mail: service@hexal. com
HEXAL AG Industriestrasse 25 D- 83607 Holzkirchen Nemčija Tel: + 49 8024 908- 0 Faks: + 49 8024 908- 1290 e- pošta: service@ hexal. com
Sandoz GmbH Biochemiestrasse 10 A-6250 Kundl Austria
Sandoz GmbH Biochemiestrasse 10 A- 6250 Kundl Avstrija
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske Agencije za zdravila European Medicines Agency (EMEA), spletna stran: http: // www. emea. europa. eu /
-------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
How do I inject myself?
Kako si sam injiciram zdravilo?
You will need to give yourself an injection into the tissue under the skin, known as a subcutaneous injection.
Injekcijo si boste morali dati v tkivo pod kožo, ta postopek pa se imenuje podkožno injiciranje.
Your doctor or nurse will tell you how frequently it should be injected.
Vaš zdravnik ali medicinska sestra vam bosta povedala, kako pogosto si morate zdravilo injicirati.
What do I need?
Kaj potrebujem?
To give yourself a subcutaneous injection you will need:
Da si boste lahko dali podkožno injekcijo, boste potrebovali:
1.
57 1.
A new pre-filled syringe of Filgrastim HEXAL with or without a needle safety guard 2.
Novo napolnjeno injekcijsko brizgo zdravila Filgrastim HEXAL z varnostno zaščito za iglo ali brez nje 2.
Alcohol wipes or similar 3.
Alkoholne robčke ali kaj podobnega 3.
A puncture-proof container for disposing of used syringes safely if you use the Filgrastim HEXAL pre-filled syringe without a needle safety guard.
Neprebodni vsebnik za varno odlaganje uporabljenih injekcijskih brizg v primeru, da uporabljate zdravilo Filgrastim HEXAL brez varnostne zaščite za iglo.
57 What should I do before I give myself a subcutaneous injection of Filgrastim HEXAL?
Kaj moram storiti preden si dam podkožno injekcijo zdravila Filgrastim HEXAL?
Take your Filgrastim HEXAL pack out of the refrigerator.
Vzemite pakiranje zdravila Filgrastim HEXAL iz hladilnika.
Accidental exposure to freezing temperatures does not adversely affect the stability of Filgrastim HEXAL.
Naključna izpostavljenost temperaturam v območju zmrzišča ne bo neugodno vplivala na stabilnost zdravila Filgrastim HEXAL.
Do not shake the packing containing the pre-filled syringe.
Pakiranja, ki vsebuje napolnjeno injekcijsko brizgo, ne stresajte.
Check that it is the correct strength you need for the dose that your doctor has prescribed.
Preverite, ali imate pravilno jakost zdravila, ki jo potrebujete za odmerek, ki vam ga je predpisal zdravnik.
Check the expiry date which is stated on the carton and syringe label (EXP).
Preverite rok uporabnosti, ki je naveden na škatli in na nalepki brizge (Uporabno do/ EXP).
Do not use it if the date has passed the last day of the month shown.
Zdravila ne uporabite, če je že pretekel zadnji dan tam navedenega meseca.
Check the appearance of Filgrastim HEXAL.
Preverite izgled zdravila Filgrastim HEXAL.
It must be clear.
Raztopina mora biti bistra.
If it is cloudy or there are particles in it, you must not use it.
Če je raztopina motna, ali se v njej nahajajo delci, je ne smete uporabiti.
For a more comfortable injection, let the pre-filled syringe stand for 30 minutes to reach room temperature or hold the pre-filled syringe gently in your hand for a few minutes.
Za udobnejše injiciranje pustite napolnjeno injekcijsko brizgo stati 30 minut, da doseže sobno temperaturo, ali pa napolnjeno injekcijsko brizgo nežno držite v roki nekaj minut.
Do not warm Filgrastim HEXAL in any other way (for example, do not warm it in a microwave or in hot water).
Zdravila Filgrastim HEXAL ne segrevajte na noben drug način (na primer, ne segrevajte ga v mikrovalovni pečici ali v vroči vodi).
Do not remove the plastic cover from the needle until you are ready to inject.
Plastičnega prekrivala ne snemite z igle dokler niste pripravljeni za injiciranje.
Find a comfortable, well-lit place and put the syringe, the alcohol wipes and if necessary the puncture-proof container where you can reach them.
Poiščite udobno, dobro osvetljeno mesto in položite brizgo, alkoholne robčke, in, če je potrebno, neprebodni vsebnik, tako, da vam bodo povsem pri roki.
Before you inject Filgrastim HEXAL you must do the following:
Pred injiciranjem zdravila Filgrastim HEXAL morate narediti naslednje:
Gently remove the plastic cover from the needle without twisting it.
Nežno snemite plastično prekrivalo z igle, ne da bi jo pri tem zvili.
Hold the syringe with the needle pointing upwards to check if there are air bubbles in the syringe.
Brizgo držite tako, da je igla obrnjena navzgor, da tako preverite, ali so v brizgi zračni mehurčki.
3.
Če so v njej zračni mehurčki iz nje iztisnite zrak tako, da pazljivo potisnete bat navzgor (pri tem pazite, da tekočina ne izteče iz brizge.) 3.
The syringe has a scale on the syringe barrel.
Na brizgi je označeno merilo.
Push the plunger up to the number (ml) that matches the dose of Filgrastim HEXAL that your doctor prescribed.
Bat potisnite do števila (ml), ki se ujema z odmerkom zdravila Filgrastim HEXAL, ki vam ga je predpisal vaš zdravnik.
Check again to make sure the correct dose of Filgrastim HEXAL is in the syringe.
Ponovno preverite, da je v brizgi pravilen odmerek zdravila Filgrastim HEXAL.
Where should I give my injection?
Kam si moram dati injekcijo?
The most suitable places to inject yourself are:
Najprimernejša mesta za dajanje injekcije samemu sebi so:
- The top of your thighs; and
- vrh stegen; in
- The abdomen, except for the area around the navel.
- trebuh, z izjemo predela okoli popka.
Change the place that you inject each time so you don’ t become sore in one area.
Mesto injiciranja vsakič menjajte, tako da ne pride do vnetja na enem področju.
If someone is injecting for you, they can also use the back of your arms.
Če vam injekcijo daje nekdo drug, je mogoče injekcijo dati tudi na zadnjo stran vaših rok (nadlakti).
How do I give my injection?
Kako si dam injekcijo?
Disinfect your skin by using an alcohol wipe and pinch the skin between your thumb and forefinger, without squeezing it.
Nato primite kožo med palec in kazalec, ne da bi jo močneje stiskali.
Insert the needle under the skin at an angle of approximately 45° as shown by your nurse or doctor.
Iglo zabodite v kožo pod kotom približno 45°, kot sta vam pokazala vaša medicinska sestra ali zdravnik.
Pull slightly on the plunger to check that a blood vessel has not been punctured.
Nekoliko izvlecite bat, tako da se boste prepričali, da niste zabodli v žilo.
If you see blood in the syringe, remove the needle and put it in another place.
Če se v brizgi pokaže kri, izvlecite iglo in jo zabodite na drugo mesto.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.
Če imate kakršnekoli težave, se za pomoč in nasvet ne obotavljajte prositi svojega zdravnika ali medicinske sestre.
Disposal of used syringes
Odlaganje rabljenih injekcijskih brizg
The used syringes should be disposed of in accordance with local requirements.
Uporabljene brizge je treba zavreči v skladu z lokalnimi predpisi.
- Do not put the cover back on used syringes.
- Prekrivala ne nameščajte nazaj na uporabljene injekcijske brizge.
- Put used syringes into the puncture-proof disposal container and keep it out of the reach and
- Rabljene injekcijske brizge dajte v neprebodni vsebnik za odlaganje, ki ga shranjujte otrokom
sight of children.
nedostopno.
- Dispose of the full container as instructed by your doctor, nurse or pharmacist.
- Ko je vsebnik poln, ga zavrzite v skladu z navodili, ki so vam jih dali vaš zdravnik, medicinska
- NEVER put used syringes into your normal household waste bin.
sestra ali farmacevt.
- The needle safety guard prevents needle stick injuries after use, so no special disposal
- Varnostna zaščita za iglo preprečuje, da bi po uporabi prišlo do poškodb z vbodom igle, tako da
precautions are required.
niso potrebni nobeni posebni previdnostni ukrepi pri odlaganju.
Dispose of the syringe as instructed by your doctor, nurse or pharmacist.
Brizgo zavrzite v skladu z navodili, ki so vam jih dali vaš zdravnik, medicinska sestra ali farmacevt.
------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only:
------------------------------------------------------------------------------------------------------------------------ Naslednje informacije so namenjene samo zdravstvenemu osebju:
If required, Filgrastim HEXAL may be diluted in glucose 50 mg/ ml (5%) solution.
Če je potrebno, se zdravilo Filgrastim HEXAL lahko razredči v 5% (50 mg/ ml) raztopini glukoze.
Dilution to a final concentration < 0.2 MU/ ml (2 μ g/ ml) is not recommended at any time.
(2 µg/ ml).
In a final volume of 20 ml, total doses of filgrastim less than 30 MU (300 μ g) should be given with 0.2 ml of human serum albumin 200 mg/ ml (20%) solution Ph.
(300 µg), dati z dodatkom 0, 2 ml 20% (200 mg/ ml) raztopine humanega albumina Ph.
59 When diluted in glucose 50 mg/ ml (5%) solution, filgrastim is compatible with glass and a variety of plastics including polyvinylchloride, polyolefin (a copolymer of polypropylene and polyethylene) and polypropylene.
Če je razredčen s 5% (50 mg/ ml) raztopino glukoze, je filgrastim kompatibilen s steklom in različnimi plastičnimi materiali, vključno s PVC, poliolefinom (kopolimerom polipropilena in polietilena) in polipropilenom.
Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C.
Kemična in fizikalna stabilnost razredčene raztopine za infundiranje sta bili dokazani za obdobje 24 ur pri temperaturi od 2°C do 8°C.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Ta čas običajno ne sme presegati 24 ur pri temperaturi od 2°C do 8°C, razen če je redčenje opravljeno v nadzorovanih in preverjenih (validiranih) aseptičnih pogojih.
Filgrastim ratiopharm is a ‘ biosimilar’ medicine.
Zdravilo Filgrastim ratiopharm je podobno biološko zdravilo.
This means that Filgrastim ratiopharm is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘ reference medicine’).
„ referenčno zdravilo “).
Filgrastim ratiopharm is used to stimulate the production of white blood cells in the following situations: • to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing); • to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at a risk of long-term, severe neutropenia; • to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections; • to treat persistent neutropenia in patients with advanced human immunodeficiency virus (HIV) infection, to reduce the risk of bacterial infections when other treatments are not appropriate.
Zdravilo Filgrastim ratiopharm se uporablja za spodbujanje tvorbe belih krvničk v naslednjih primerih: • za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvničk) in zmanjšanje pojava febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki prejemajo kemoterapijo (zdravljenje proti raku), ki je citotoksična (ubija celice); • za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo s terapijo, katere cilj je uničenje celic kostnega mozga pred presaditvijo kostnega mozga (kot npr. pri bolnikih z levkemijo), pri katerih obstaja tveganje za dlje trajajočo hudo nevtropenijo; • za povečanje števila nevtrofilcev in zmanjšanje tveganja za okužbe pri bolnikih z nevtropenijo, ki so imeli v preteklosti hujše, ponavljajoče se okužbe; • za zdravljenje netropenije pri bolnikih z napredovalo okužbo z virusom humane imunske pomanjkljivosti (HIV), z namenom zmanjšanja tveganja za bakterijske okužbe, ko druge oblike zdravljenja niso primerne.
Reproduction is authorised provided the source is acknowledged.
Za več informacij glejte navodilo za uporabo.
The active substance in Filgrastim ratiopharm, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF).
Učinkovina v zdravilu Filgrastim ratiopharm, filgrastim, je zelo podobna človeški beljakovini, imenovani granulocitne kolonije stimulirajoči faktor (granulocyte colony stimulating factor - G- CSF).
To study the safety of Filgrastim ratiopharm, two further studies were carried out in patients with lung cancer and with non-Hodgkin’ s lymphoma.
Za preučitev varnosti zdravila Filgrastim ratiopharm sta bili izvedeni še dve študiji z bolniki s pljučnim rakom in z neHodgkinovim limfomom.
During the first 21-day chemotherapy cycle, patients treated with either Filgrastim ratiopharm or Neupogen had severe neutropenia for an average of 1.1 days, compared with 3.8 days in those receiving placebo.
Med prvim 21 dnevnim ciklom kemoterapije so imeli bolniki, zdravljeni bodisi z zdravilom Filgrastim ratiopharm ali Neupogen, hudo netropenijo v povprečju 1, 1 dan, v primerjavi s 3, 8 dnevi pri tistih, ki so prejemali placebo.
Therefore, the CHMP’ s view was that, as for Neupogen, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da so koristi zdravila Filgrastim ratiopharm, tako kot pri zdravilu Neupogen, večje od znanih tveganj.
Filgrastim ratiopharm 30 MIU/ 0.5 ml solution for injection or infusion
Filgrastim ratiopharm 30 000 k. i. e. / 0, 5 ml raztopina za injiciranje ali infundiranje
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/ l, and a history of severe or recurrent infections, long term administration of Filgrastim ratiopharm is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Bolnikom, otrokom ali odraslim s hujšo obliko kongenitalne, ciklične ali idiopatične nevtropenije z absolutnim številom nevtrofilcev (ANC) 0, 5 × 109/ l in s hujšimi ali ponavljajočimi se okužbami, se dolgotrajno jemanje zdravila Filgrastim ratiopharm predpiše zato, da se poveča število nevtrofilcev in zmanjša pogostost nastanka in trajanja z okužbami povezanih pojavov.
Filgrastim ratiopharm is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/ l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Zdravilo Filgrastim ratiopharm se uporablja za zdravljenje dolgotrajne nevtropenije (ANC manjše ali enako 1, 0 × 109/ l) pri bolnikih z napredovalo okužbo HIV, z namenom zmanjšanja tveganja bakterijskih okužb, ko druge oblike zdravljenja nevtropenije niso primerne.
Neutrophil count > 1.0 x 109/ l for 3 consecutive days 9
Število nevtrofilcev > 1, 0 x 109/ l 3 zaporedne dni Če absolutno število nevtrofilcev ostane > 1, 0 x 109/ l tri zaporedne dni
Filgrastim dose adjustment Reduce to 0.5 MIU (5 µg)/ kg/ day
Prilagoditev odmerka filgrastima Zmanjšajte na 0, 5 x 106i. e.
Then, if ANC remains > 1.0 x 10 / l for 3 more consecutive days
(5 µg) / kg/ dan Prekinite zdravljenja s filgrastimom
Discontinue filgrastim
Če se med zdravljenjem absolutno število nevtrofilcev odmerek filgrastima povečati, kot je opisano zgoraj.
If the ANC decreases to < 1.0 x 109/ l during the treatment period the dose of filgrastim should be re- escalated according to the above steps
zmanjša, tako da je vrednost < 1, 0 x 109/ l, je treba
Leukapheresis should be performed during the period when the ANC rises from< 0.5 x 109/l to > 5.0 x 109/l.
(5 μg) / kg/ dan v obliki subkutane injekcije od prvega dne po koncu kemoterapije, pa dokler pričakovani padec števila nevtrofilcev ne preide na višji nivo in se število nevtrofilcev ne povrne na običajno raven.
The safety and efficacy of filgrastim have not been assessed in normal donors< 16 years or > 60 years.
Varnost in učinkovitost zdravila filgrastim pri običajnih darovalcih, mlajših od 16 let ali starejših od 60. let, nista bili ocenjeni.
Filgrastim ratiopharm contains sorbitol.
9 Zdravilo Filgrastim ratiopharm vsebuje sorbitol.
Filgrastim ratiopharm containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Zdravilo Filgrastim ratiopharm, ki vsebuje rekombinantni človeški G- CSF (filgrastim) v 24- ih urah povzroči izrazito zvišanje števila nevtrofilcev v periferni krvi, medtem ko je zvišanje monocitov manjše.
The efficacy and safety of Filgrastim ratiopharm has been assessed in randomised, controlled phase III studies in breast cancer, lung cancer and Non-Hodgkin-Lymphoma.
14 Učinkovitost in varnost Filgrastim ratiopharma sta bili ocenjeni v randomiziranih in nadzorovanih študijah faze III pri bolnikih z rakom dojk, rakom na pljučih in Ne- Hodkinovim limfomom.
15 Filgrastim ratiopharm should not be diluted with sodium chloride solution.
Zdravila Filgrastim ratiopharm ne smemo mešati z raztopino natrijevega klorida.
Diluted filgrastim may be adsorbed to glass and plastic materials except diluted, as mentioned in section 6.6.
15 Če ni razredčeno v skladu z navodili v poglavju 6. 6, se razredčen filgrastim lahko adsorbira na steklene in plastične materiale.
If required, Filgrastim ratiopharm may be diluted in glucose 50 mg/ ml (5%) solution for infusion.
Če je potrebno, lahko zdravilo Filgrastim ratiopharm razredčite v glukozi 50 mg/ ml (5%) raztopini za infundiranje.